Alterity Therapeutics Files 6-K on Substantial Holding Change
Ticker: PRNAF · Form: 6-K · Filed: Jul 28, 2025 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Jul 28, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: substantial-holding, filing-update, pharmaceutical
Related Tickers: ATHE
TL;DR
Alterity Therapeutics (ATHE) filed a 6-K for a substantial holding change; check filings for details.
AI Summary
Alterity Therapeutics Limited filed a Form 6-K on July 28, 2025, to report a change in substantial holding. The filing is incorporated by reference into several of their existing registration statements on Form S-8 and Form F-3. The company, formerly known as PRANA BIOTECHNOLOGY LTD, is a development stage enterprise focused on pharmaceutical preparations.
Why It Matters
This filing indicates a significant shift in ownership for Alterity Therapeutics, which could impact its stock price and strategic direction.
Risk Assessment
Risk Level: medium — Filings related to changes in substantial holdings can signal shifts in investor confidence or strategic maneuvering, warranting closer attention.
Key Players & Entities
- Alterity Therapeutics Limited (company) — Filer of the 6-K report
- PRANA BIOTECHNOLOGY LTD (company) — Former name of Alterity Therapeutics Limited
- July 2025 (date) — Reporting period for the Form 6-K
- 20250728 (date) — Filing date of the Form 6-K
- Form S-8 (document) — Registration statement into which the 6-K is incorporated
- Form F-3 (document) — Registration statement into which the 6-K is incorporated
FAQ
What specific change in substantial holding is reported in the 6-K filing?
The filing explicitly mentions 'Change in substantial holding' as Exhibit 99.1, but the details of the change are not provided in the provided text.
What is the primary business of Alterity Therapeutics Limited?
Alterity Therapeutics Limited is classified under 'PHARMACEUTICAL PREPARATIONS [2834]' and is described as a development stage enterprise.
Into which existing registration statements is this Form 6-K being incorporated?
This Form 6-K is being incorporated by reference into Alterity Therapeutics' Registration Statements on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076).
When was Alterity Therapeutics Limited formerly known as?
Alterity Therapeutics Limited was formerly known as PRANA BIOTECHNOLOGY LTD, with a date of name change on January 5, 2001.
What is the principal executive office address of Alterity Therapeutics Limited?
The principal executive office is located at Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on July 28, 2025 regarding ALTERITY THERAPEUTICS LTD (PRNAF).